Kasatwar Aakash, Shukla Ravindra, Rathod Nivrutti, Nandanwar Jayshri, Mishra Divyangi, Dhobley Akshay
Department of Public Health, General Hospital Chandrapur, Maharashtra, India.
Department of Endocrinology and Metabolism, All India Institute of Medical Sciences Jodhpur, Jodhpur, Rajasthan, India.
IJID Reg. 2022 Dec;5:21-29. doi: 10.1016/j.ijregi.2022.08.005. Epub 2022 Aug 24.
Coronavirus disease 2019 (COVID-19)-associated mucormycosis (CAM) became a public health problem in India in 2021. However, information about the incidence, presentation and prognosis of CAM remains sparse.
This study describes 100 cases from the Surgically treated Post COVID Acute invasive fungal Rhino-Orbital Sinusitis in Chandrapur (SPAROS) study, a prospective observational follow-up study of patients with CAM diagnosed in Chandrapur district, India. Two-step cluster analysis using four input variables - blood glucose on admission, diabetes status, glucocorticoid exposure and severity of COVID-19 - was used to define three distinct CAM clusters.
The incidence of CAM in the general population was 7.1 cases/1000 patients hospitalized with COVID-19. Steroid exposure and pre-existing diabetes were present in 76% and 55% of cases, respectively. At median follow-up of 18 days, only two deaths had been recorded, while 93 cases were stable. Glucocorticoids, particularly methylprednisolone, seemed to precipitate CAM. Admission to the intensive care unit appeared to be predictive of less extensive surgery.
Three subtypes of CAM were identified: COVID-19-associated diabetes and mucormycosis, COVID-19-associated classical mucormycosis, and COVID-19-induced mucormycosis. A CAM hypothesis was proposed based on the dynamics of severe acute respiratory syndrome coronavirus-2 and glucose regulated protein.
The clinical characteristics, natural course and pathogenesis of CAM differ from mucormycosis in the pre-COVID era. It is hoped that this classification will be useful in CAM management.
2019年冠状病毒病(COVID-19)相关毛霉病(CAM)在2021年成为印度的一个公共卫生问题。然而,关于CAM的发病率、表现和预后的信息仍然稀少。
本研究描述了来自钱德拉布尔COVID后急性侵袭性真菌性鼻-眶-鼻窦炎手术治疗(SPAROS)研究的100例病例,这是一项对印度钱德拉布尔地区诊断为CAM的患者进行的前瞻性观察随访研究。使用入院时血糖、糖尿病状态、糖皮质激素暴露和COVID-19严重程度这四个输入变量进行两步聚类分析,以定义三个不同的CAM聚类。
普通人群中CAM的发病率为每1000例因COVID-19住院的患者中有7.1例。分别有76%和55%的病例存在类固醇暴露和既往糖尿病史。在18天的中位随访期内,仅记录到两例死亡,而93例病情稳定。糖皮质激素,尤其是甲泼尼龙,似乎会诱发CAM。入住重症监护病房似乎预示着手术范围较小。
确定了CAM的三种亚型:COVID-19相关糖尿病和毛霉病、COVID-19相关经典毛霉病以及COVID-19诱发的毛霉病。基于严重急性呼吸综合征冠状病毒2和葡萄糖调节蛋白的动态变化提出了一个CAM假说。
CAM的临床特征、自然病程和发病机制与COVID-19大流行前时代的毛霉病不同。希望这种分类对CAM的管理有用。